News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
529,077 Results
Type
Article (44990)
Company Profile (117)
Press Release (483970)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (145078)
Career Advice (2401)
Deals (27951)
Drug Delivery (120)
Drug Development (68043)
Employer Resources (151)
FDA (15663)
Job Trends (11974)
News (263944)
Policy (29667)
Tag
2024 BioCapital Digital (5)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (2)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (4)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2302)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (78)
Alliances (36010)
ALS (86)
Alzheimer's disease (1430)
Antibody-drug conjugate (ADC) (133)
Approvals (15618)
Artificial intelligence (237)
Autoimmune disease (27)
Automation (12)
Bankruptcy (311)
Best Places to Work (9197)
BIOSECURE Act (22)
Biosimilars (114)
Biotechnology (70)
Bladder cancer (68)
Brain cancer (26)
Breast cancer (254)
Cancer (2035)
Cardiovascular disease (183)
Career advice (2007)
Career pathing (33)
CAR-T (141)
Cell therapy (397)
Cervical cancer (19)
Clinical research (55311)
Collaboration (697)
Compensation (520)
Complete response letters (29)
COVID-19 (2597)
CRISPR (41)
C-suite (214)
Cystic fibrosis (94)
Data (1915)
Decentralized trials (2)
Denatured (14)
Depression (50)
Diabetes (261)
Diagnostics (5253)
Digital health (15)
Diversity (4)
Diversity, equity & inclusion (42)
Drug discovery (101)
Drug pricing (121)
Drug shortages (30)
Duchenne muscular dystrophy (96)
Earnings (58698)
Editorial (43)
Employer branding (20)
Employer resources (136)
Events (77107)
Executive appointments (637)
FDA (16853)
Featured Employer (33)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (631)
Gene editing (101)
Generative AI (22)
Gene therapy (300)
GLP-1 (788)
Government (3899)
Grass and pollen (6)
Guidances (47)
Healthcare (14827)
Huntington's disease (24)
IgA nephropathy (26)
Immunology and inflammation (136)
Indications (25)
Infectious disease (2743)
Inflammatory bowel disease (128)
Inflation Reduction Act (9)
Influenza (49)
Intellectual property (86)
Interviews (449)
IPO (13992)
IRA (48)
Job creations (3159)
Job search strategy (1666)
Kidney cancer (11)
Labor market (32)
Layoffs (507)
Leadership (21)
Legal (6967)
Liver cancer (71)
Lung cancer (290)
Lymphoma (141)
Machine learning (6)
Management (51)
Manufacturing (285)
MASH (69)
Medical device (11210)
Medtech (11213)
Mergers & acquisitions (14452)
Metabolic disorders (714)
Multiple sclerosis (73)
NASH (22)
Neurodegenerative disease (94)
Neuropsychiatric disorders (33)
Neuroscience (1946)
NextGen: Class of 2025 (4987)
Non-profit (3165)
Northern California (2396)
Now hiring (17)
Obesity (398)
Opinion (218)
Ovarian cancer (66)
Pain (81)
Pancreatic cancer (76)
Parkinson's disease (146)
Partnered (16)
Patents (225)
Patient recruitment (96)
Peanut (44)
People (42703)
Pharmaceutical (33)
Pharmacy benefit managers (21)
Phase I (16550)
Phase II (23937)
Phase III (19683)
Pipeline (1123)
Policy (163)
Postmarket research (2206)
Preclinical (6675)
Press Release (28)
Prostate cancer (98)
Psychedelics (35)
Radiopharmaceuticals (210)
Rare diseases (388)
Real estate (4261)
Recruiting (60)
Regulatory (20927)
Reports (31)
Research institute (2058)
Resumes & cover letters (401)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (74)
Series A (121)
Series B (78)
Service/supplier (9)
Sickle cell disease (54)
Southern California (2028)
Special edition (16)
Spinal muscular atrophy (128)
Sponsored (33)
Startups (2747)
State (1)
Stomach cancer (16)
Supply chain (71)
Tariffs (38)
The Weekly (66)
United States (20078)
Vaccines (755)
Venture capitalists (43)
Weight loss (291)
Women's health (31)
Worklife (19)
Date
Today (38)
Last 7 days (589)
Last 30 days (2210)
Last 365 days (29593)
2025 (9205)
2024 (31404)
2023 (34984)
2022 (45060)
2021 (48499)
2020 (45511)
2019 (36216)
2018 (27398)
2017 (27813)
2016 (25804)
2015 (27975)
2014 (21777)
2013 (17793)
2012 (18968)
2011 (19381)
2010 (17506)
Location
Africa (671)
Alabama (40)
Alaska (6)
Arizona (167)
Arkansas (10)
Asia (31081)
Australia (5457)
California (5378)
Canada (1477)
China (399)
Colorado (231)
Connecticut (261)
Delaware (127)
Europe (75625)
Florida (813)
Georgia (179)
Hawaii (1)
Idaho (36)
Illinois (428)
India (24)
Indiana (241)
Iowa (11)
Japan (142)
Kansas (82)
Kentucky (13)
Louisiana (7)
Maine (61)
Maryland (820)
Massachusetts (4051)
Michigan (176)
Minnesota (319)
Mississippi (1)
Missouri (70)
Montana (12)
Nebraska (19)
Nevada (53)
New Hampshire (50)
New Jersey (1534)
New Mexico (14)
New York (1498)
North Carolina (876)
North Dakota (6)
Northern California (2396)
Ohio (154)
Oklahoma (8)
Oregon (28)
Pennsylvania (1171)
Puerto Rico (9)
Rhode Island (20)
South America (1037)
South Carolina (20)
South Dakota (1)
Southern California (2028)
Tennessee (86)
Texas (760)
Utah (142)
Virginia (125)
Washington D.C. (59)
Washington State (497)
West Virginia (3)
Wisconsin (51)
529,077 Results for "almirall prodesfarma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
FDA Approves Almirall’s Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp up to 100 cm2
Almirall, a global pharmaceutical company dedicated to medical dermatology, announced that the U.S. Food and Drug Administration has approved Almirall’s recent supplemental New Drug Application to expand the use area for its drug, Klisyri, to up to 100 cm2.
June 10, 2024
·
6 min read
Press Releases
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
February 24, 2025
·
19 min read
Press Releases
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
November 11, 2024
·
7 min read
Business
Almirall’s Nine-month 2023 Results:
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its 9M 2023.
November 9, 2023
·
19 min read
Press Releases
Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth
January 14, 2025
·
6 min read
Press Releases
Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025
March 6, 2025
·
3 min read
Press Releases
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin
March 10, 2025
·
7 min read
Business
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013.
March 13, 2024
·
7 min read
Press Releases
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
September 25, 2024
·
8 min read
Business
Almirall’s First Quarter 2023 Results
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its Q1 2023 financial results.
May 8, 2023
·
11 min read
1 of 52,908
Next
